196 related articles for article (PubMed ID: 21805124)
1. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Cichero E; Fossa P
J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
[TBL] [Abstract][Full Text] [Related]
2. Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses.
Cichero E; Cesarini S; Spallarossa A; Mosti L; Fossa P
J Mol Model; 2009 Jul; 15(7):871-84. PubMed ID: 19153780
[TBL] [Abstract][Full Text] [Related]
3. Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.
Cichero E; Cesarini S; Fossa P; Spallarossa A; Mosti L
Eur J Med Chem; 2009 May; 44(5):2059-70. PubMed ID: 19046616
[TBL] [Abstract][Full Text] [Related]
4. 3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.
Cichero E; Buffa L; Fossa P
J Mol Model; 2011 Jul; 17(7):1537-50. PubMed ID: 20922443
[TBL] [Abstract][Full Text] [Related]
5. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
6. Computational studies of the binding mode and 3D-QSAR analyses of symmetric formimidoester disulfides: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitor.
Cichero E; Cesarini S; Spallarossa A; Mosti L; Fossa P
J Mol Model; 2009 Apr; 15(4):357-67. PubMed ID: 19066996
[TBL] [Abstract][Full Text] [Related]
7. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Sivan SK; Manga V
J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
Xu HR; Fu L; Zhan P; Liu XY
SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
Vanangamudi M; Poongavanam V; Namasivayam V
Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
[TBL] [Abstract][Full Text] [Related]
12. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
13. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.
Santos LH; Ferreira RS; Caffarena ER
Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):847-64. PubMed ID: 26560977
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
15. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
Wu HQ; Yao J; He QQ; Chen FE
SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
[TBL] [Abstract][Full Text] [Related]
16. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
17. Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
Mowbray CE; Burt C; Corbau R; Perros M; Tran I; Stupple PA; Webster R; Wood A
Bioorg Med Chem Lett; 2009 Oct; 19(19):5599-602. PubMed ID: 19709880
[TBL] [Abstract][Full Text] [Related]
18. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
19. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
20. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
